To circumvent this challenge, we propose: (i) tumor‐selective delivery platforms enabling spatiotemporal precision, or (ii) repurposing clinically validated agents with established safety profiles—such as OXPHOS inhibitors (CPI‐613),[38] canonical CDC42 inhibitors (MBQ‐167),[39] and recently developed CDC42 antagonists (Daphnepedunin A).[40]. Here, CDC42 is linked to neoplasm.